Eikon Therapeutics Funding & Investors
Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.
https://eikontx.com/Total Amount Raised: $772,000,000
Eikon Therapeutics Funding Rounds
Series C
$106,000,000
Series B
$518,000,000
Series B Investors
EcoR1 CapitalHartford HealthCare EndowmentHarel Insurance InvestmentsSoros Capital ManagementLux CapitalThe Column GroupInnovation EndeavorsStepStone GroupSchroders CapitalGeneral CatalystUC InvestmentsAME Cloud VenturesE15 VCCPP InvestmentsForesite CapitalT. Rowe PriceAbu Dhabi Investment AuthorityHorizons VenturesSeries A
$148,000,000
Series A Investors
Lux CapitalWPSS.bioForesite CapitalTCG CrossoverThe Column GroupInnovation Endeavors
Funding info provided by Diffbot.